Clinical trials
Acute Myeloid Leukemia in Remission clinical trials
Below are recruiting acute myeloid leukemia in remission clinical trials, each written for real people, not researchers. We’re tracking 175 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07153068RecruitingPhase 1/Phase 2
SupCD7 CART therapy for CD7 positive blood cancers
This trial tests a special immune cell therapy (SupCD7 CART) that targets a protein called CD7 on cancer cells. It is for people with certain types of blood cancers (like T-ALL/LBL or AML) that have come back or not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07109518RecruitingPhase 1
CD7 CAR T-Cell Therapy for Blood Cancers That Return or Don't Respond
This trial tests a new CAR T-cell therapy targeting CD7, a protein on some blood cancer cells. It is designed for patients whose T-cell leukemia/lymphoma or other CD7-positive blood cancer has not responded to standard treatments or has returned.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07025824RecruitingPhase 2
Comparing two chemo drugs for stem cell transplant in AML and MDS
This trial compares two chemotherapy drugs, treosulfan and melphalan, used before a stem cell transplant in people with AML or MDS. The goal is to see which one works better with a special anti-rejection drug called PTCy.
AachenAges 18 years+ - NCT06996119RecruitingPhase 1
Preventing graft-versus-host disease after stem cell transplant
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT06812104RecruitingPhase 1
A trial of KK2845 for certain blood cancers
This trial is testing a new drug, KK2845, for people with certain blood cancers that have come back or not responded to treatment. It focuses on acute myeloid leukemia (AML) and other blood cancers.
Kamogawa, ChibaAges 18 years+ - NCT06786533RecruitingPhase 1
CAR-T cells for hard-to-treat AML
This study tests a new treatment made from your own immune cells, engineered to find and attack AML cells. It is for patients whose leukemia has not responded to standard therapy or has come back after treatment, including after a stem cell transplant.
Houston, TexasAges 12 years+ - NCT06707493RecruitingPhase 2
Ivosidenib after stem cell transplant for IDH1-mutated AML
This study tests whether a daily pill called ivosidenib can help prevent AML from coming back after a stem cell transplant. It is for people whose AML has a specific IDH1 gene change and who are planning to have a transplant.
Atlanta, GeorgiaAges 18–75 - NCT06690827RecruitingPhase 1
Cd123-targeted car-nk cells for relapsed aml or bpdcn
This trial tests a new treatment using your own immune cells (natural killer cells) that are modified to find and attack cancer cells with a marker called CD123. It is for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard therapies.
Wuhan, HubeiAges 18–75 - NCT06557421RecruitingPhase 2
Stopping venetoclax and azacitidine in AML remission
This trial tests whether it's safe to stop the combination of venetoclax and azacitidine (VEN-AZA) in people with AML whose cancer has completely disappeared and who have no detectable leukemia cells left. If you've been on VEN-AZA for about a year and are in deep remission, this study may help you avoid unnecessary treatment.
MarseilleAges 18 years+ - NCT06511882RecruitingPhase 2
Stopping AML treatment after reaching remission with no detectable disease
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
Tampa, FloridaAges 18 years+ - NCT06284486RecruitingPhase 1/Phase 2
Venetoclax and revumenib for AML with residual disease
This trial tests two targeted drugs, venetoclax and revumenib, for people with acute myeloid leukemia (AML) that has a specific change in the NPM1, KMT2A, or NUP98 genes and has minimal residual disease (MRD) after treatment. The goal is to see if this combination can clear remaining leukemia cells and improve outcomes.
Baltimore, MarylandAges 12 years+ - NCT05945849RecruitingPhase 1
Modified stem cells and CAR T cells for hard-to-treat AML
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03828773Recruiting
Azole antifungal prevention for leukemia during low white blood counts
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
Ghent, BelgiumAges 18 years+ - NCT02416388RecruitingPhase 2/Phase 3
Trial for AML treatments and preventing graft-versus-host disease
This trial tests different chemotherapy induction, consolidation (follow-up treatment), and strategies to prevent complications after an allogeneic stem cell transplant. It aims to improve overall survival and reduce serious transplant side effects like graft-versus-host disease (GVHD).
AmiensAges 18–61 - NCT06076226Recruiting
Donor telomere length and leukemia transplant outcomes
This trial looks at whether the length of telomeres (the protective caps at the ends of chromosomes) in donor blood cells affects recovery for people with acute leukemia who receive a stem cell transplant. It aims to see if a simple donor blood test can predict how well the transplant works.
Hangzhou, ZhejiangAges 5–90 - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT06315309RecruitingPhase 2
Two-step ATG to prevent GVHD after stem cell transplant
This trial tests a two-step use of ATG (a drug that calms immune cells) to help prevent graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from a donor. It may be an option for people with certain blood cancers or disorders who are getting a strong, marrow-clearing transplant.
Birmingham, AlabamaAges 18–60 - NCT07003737Recruiting
Blinatumomab before stem cell transplant for high-risk B-ALL
This trial tests giving a drug called blinatumomab before a stem cell transplant for people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) that is in remission and has no detectable cancer cells. The goal is to see if this extra treatment helps prevent the leukemia from coming back after transplant.
Hangzhou, ZhejiangAges 18–65 - NCT06788756RecruitingPhase 2/Phase 3
Testing L-Annamycin plus Cytarabine for relapsed AML
This trial tests whether the combination of two chemotherapy drugs, L-Annamycin and Cytarabine, can help adults whose acute myeloid leukemia (AML) has come back or not responded to one prior treatment. The goal is to see if this combination can lead to remission.
Birmingham, AlabamaAges 18–80 - NCT06130579RecruitingPhase 2
Interferon-α for TP53-mutated blood cancer after transplant
This trial tests whether a medicine called interferon-α can help people with a specific gene mutation (TP53) in their blood cancer after they've had a donor stem cell transplant. It aims to prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 12–65 - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT07396480RecruitingPhase 3
Add-on Venetoclax before stem cell transplant for AML/MDS
This trial tests adding venetoclax to the usual chemotherapy (fludarabine and melphalan) given before a stem cell transplant for older adults with AML or MDS. The goal is to see if the combination helps prevent the disease from coming back after transplant.
Fuzhou, FujianAges 50–75 - NCT07559695Recruiting
Menin inhibitor maintenance therapy after stem cell transplant
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
Suzhou, JiangsuAges 15 years+ - NCT07591649RecruitingPhase 1/Phase 2
NK cells for high-risk blood cancers before transplant
This study tests a new type of immune cell therapy (called AdaptNK cells) for patients with high-risk myeloid diseases (blood cancers affecting bone marrow cells) who are preparing for a stem cell transplant. The goal is to help control the cancer and prepare your body for the transplant.
Minneapolis, MinnesotaAges 18 years+
Hear when a new Acute Myeloid Leukemia in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute myeloid leukemia in remission?
- Yes. Clin2 currently lists 175 recruiting acute myeloid leukemia in remission studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute myeloid leukemia in remission trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute myeloid leukemia in remission trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.